Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) shares saw strong trading volume on Thursday . 105,365 shares changed hands during mid-day trading, an increase of 247% from the previous session's volume of 30,375 shares.The stock last traded at $7.78 and had previously closed at $7.21.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Aligos Therapeutics in a report on Wednesday.
Check Out Our Latest Analysis on ALGS
Aligos Therapeutics Trading Up 25.2 %
The firm's fifty day moving average price is $10.69 and its 200 day moving average price is $13.65. The stock has a market capitalization of $705.33 million, a price-to-earnings ratio of -7.05 and a beta of 2.16.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million for the quarter. During the same quarter in the prior year, the company posted ($10.75) earnings per share. On average, analysts forecast that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aligos Therapeutics
Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its stake in Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company's stock worth $644,000 after buying an additional 98,628 shares during the period. Opaleye Management Inc. increased its stake in Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock worth $1,597,000 after buying an additional 333,000 shares during the period. Finally, Armistice Capital LLC increased its stake in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock worth $2,540,000 after buying an additional 363,000 shares during the period. 60.43% of the stock is currently owned by institutional investors and hedge funds.
About Aligos Therapeutics
(
Get Free Report)
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Articles
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
